Percutaneous transhepatic treatment of symptomatic mesenteric venous thrombosis  by Lopera, Jorge E. et al.
Percutaneous transhepatic treatment of
symptomatic mesenteric venous thrombosis
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Three patients were seen with acute mesenteric venous thrombosis. With a transhepatic access, percutaneous pharmaco-
logic thrombolysis was performed in one patient with extensive thrombosis of the portal and mesenteric veins, resulting
in complete thrombolysis of the portal vein and partial thrombolysis of the superior mesenteric vein. In two patients with
focal thrombosis, the use of mechanical devices achieved complete thrombolysis. Percutaneous thrombolysis of portal and
mesenteric veins with a transhepatic approach, followed by coil embolization, is a promising endovascular technique for
treatment of symptomatic acute mesenteric venous thrombosis. (J Vasc Surg 2002;36:1058-61.)
Mesenteric venous thrombosis (MVT) is an uncom-
mon form of intestinal ischemia. Exploratory laparotomy
with resection of the infarcted bowel and aggressive anti-
coagulant therapy are the standard of care. Morbility and
mortality rates can be significant because of delay in the
diagnosis resulting from the unspecific clinical presenta-
tion.1,2
Endovascular techniques are a promising new alterna-
tive for the treatment of MVT. Case reports of successful
treatment of MVT include intrarterial infusion of throm-
bolytics and transjugular and transhepatic mechanical or
pharmacologic thrombolysis.3-9 We describe three patients
with acute symptomatic thrombosis of the mesenteric sys-
tem who underwent successful treatment with a transhe-
patic approach with pharmacologic thrombolysis in one
case and mechanical thrombolysis in two cases, followed by
embolization of the liver tract.
CASE REPORT
Case 1. A 30 year-old woman was seen with a 1-week history
of severe abdominal pain and distention. The medical history was
significant for hereditary spherocytosis with splenectomy during
childhood; she also had recent intake of estrogen-containing con-
traceptives. Computed tomographic (CT) scan showed acute
thrombosis of the superior mesenteric vein (SMV) and intrahepatic
and extrahepatic portal veins (Fig 1, A). The patient was placed on
intravenous anticoagulation therapy for 7 days but severe abdom-
inal pain persisted that precluded any oral intake. Percutaneous
treatment was performed with a right transhepatic approach.
Venogram revealed diffuse thrombosis of the SMV and portal veins
(Fig 1, B). A 20 cm–length infusion catheter (Angiodynamics Inc,
Queensbury, NY) was placed from the distal SMV into the main
portal vein. The symptoms resolved completely after 12 hours of
urokinase infusion at 100,000 U/h. Control venogram showed
significant improvement of the thrombosis (Fig 1, C).The infusion
was continued for a total of 36 hours. The tract was embolized
with two metallic Gianturco coils (Cook, Bloomington, Ind).
Control CT scan 2 days later showed patent portal vein with
residual nonocclusive thrombus in the SMV (Fig 1, D). The
patient was placed on long-term anticoagulation therapy and is
currently asymptomatic 36 months after the procedure. Follow-up
Doppler ultrasound scan has been performed every year after
treatment and shows a patent portal system.
Case 2. A 30-year-old man was seen with a 2-week history of
diffuse abdominal pain and diarrhea; he had continuous abdominal
pain and poor tolerance to oral intake. Doppler ultrasound scan of
the liver showed thrombosis of the portal vein; CT scan confirmed
extension of the clot into the SMV. The patient was placed on
anticoagulation therapy for 5 days, but symptoms continued.
Transhepatic venogram revealed thrombosis of the confluence of
the portal vein with the SMV. With a flexible 6F introducer (Arrow
International, Reading, Pa), percutaneous mechanical thrombec-
tomy was performed with an 6F Oasis device (Boston Scientific,
Natick, Mass). Venogram showed complete resolution of the
thrombosis. The tract was embolized with coils. The symptoms of
the patient disappeared, and he was discharged the following day.
Extensive laboratory work-up revealed a previously undiagnosed
antiphospolipid syndrome. The patient was placed on oral antico-
agulation therapy. Follow-up CT scan 3 days after treatment
showed complete resolution of the thrombosis. Follow-up ultra-
sound scan at 3 months revealed a patent mesenteric and portal
system. Patient is currently asymptomatic 5 months after treat-
ment.
Case 3. A 62-year-old woman was seen with a 3-day history
of severe abdominal pain and a 1-day history of bloody diarrhea.
The medical history was significant for previous sigmoidectomy for
colonic volvulus 1 year ago. CT scan of the abdomen showed
thrombosis of the SMV with dilated and thickened walls of the
small bowel loops (Fig 2, A). No clinical signs of peritonitis were
seen. A transhepatic percutaneous approach with ultrasound scan
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guidance revealed thrombosis of the proximal SMV and main
portal vein (Fig 2, B). Several attempts at thrombolysis with an
Oasis catheter failed to remove the thrombus. Through a 7F
introducer, an Arrow-Trerotola device (Arrow) was activated for
10 seconds. Control venogram showed a patent SMV with no
residual thrombus. The portal vein was also patent without evi-
dence of distal embolization (Fig 2, C). The tract was embolized
with metallic coils. CT scan performed 2 days later showed a patent
SMV (Fig 2, D). The patient recovered uneventfully, the diarrhea
disappeared, and oral intake was tolerated the day after the proce-
dure. The patient was placed on oral anticoagulation therapy, and
no precipitating factor for MVT was shown. The patient is asymp-
tomatic after a 3-month follow-up.
DISCUSSION
MVT is a rare but serious form of mesenteric ischemia.
The clinical presentation may vary from an asymptomatic
condition to intestinal infarction and shock.1,2 Delay in the
diagnosis is common because of the nonspecific symptoms;
the mortality rate in recent series varies from 13% to
50%.2,10 MVT has been associated with portal hyperten-
sion, abdominal infection and inflammation, trauma, sur-
gery, and hypercoagulable states, such as deficiencies of
antithrombin III, protein C, protein S, and factor V Lei-
den, and with use of estrogen–containing compounds.
Many of the formerly reported cases of primary or idio-
pathic MVT are now explained by inherited thrombophilic
disorders.1,11
The natural history of the disease is still unknown.
Patients with acute MVT with peritoneal signs need
prompt surgical exploration with resection of the infarcted
bowel.12,13 Other patients may have subacute ischemia
develop that may progress to small bowel stenosis.14 Pa-
tients with chronic MVT may be completely asymptomatic
or may have portal hypertension develop with bleeding
from gastric or esophageal varices.15 Early anticoagulation
therapy in MVT has been shown to decrease the recurrence
rate and to improve survival. In recent series, early diagnosis
and aggressive treatment with anticoagulation has resulted
in lower mortality rates than previously reported.16,17
Fig 1. A, Contrast-enhanced CT scan shows extensive thrombosis of intrahepatic branches of portal vein (arrows). B,
Digital subtraction venogram, anteroposterior view, contrast injection venogram through infusion catheter, reveals
diffuse thrombosis of portal vein (arrow) and proximal SMV (curved arrow). C, Digital subtraction venogram after
thrombolysis, anteroposterior view, shows significant improvement of flow in main portal vein (arrow) and SMV
(curved arrow). D, Control CT scan after thrombolysis shows patent intrahepatic branches of portal vein (arrows).
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When the diagnosis is confirmed early, nonoperative man-
agement results in similar morbidity, mortality, and survival
rates to initial surgical approach.18 Despite the use of early
anticoagulation therapy, transmural infarction may still oc-
cur in 18% and extrahepatic portal hypertension in 25% of
the patients with acute MVT.18
In patients with symptomatic MVT, endovascular
treatment has been reported with encouraging initial re-
sults. Possible routes of treatment include indirect intrarte-
rial infusion of thrombolytics through the superior mesen-
teric artery and direct access to the portal vein with
transjugular or transhepatic routes.3-9 Because MVT is a
rare condition, the number of cases reported is limited, and
comparison of the different routes of treatment is not
possible. Indirect intrarterial infusion of thrombolytics is
less technically demanding and has the theoretic advantage
of lysis of the small venules of the mesentery.3,4 Some
authors believe, however, that indirect lysis is more unpre-
dictable because of preferential flow into collaterals; this
technique is generally associated with longer infusion
times.6
Access to the portal vein with transjugular or transhe-
patic routes for pharmacologic or mechanical thrombolysis
have the mechanical advantage of a direct approach to the
system; the placement of an infusion catheter through the
occluded segment results in higher thrombolytic activity,
decreasing significantly the treatment time. An additional
advantage of the direct access to the portal system is that
adjunct therapies, such as balloon dilatation, balloon em-
bolectomy, and stent placement, are also possible.6,7 The
transjugular approach is generally performed with the cre-
ation of a transjugular intrahepatic portosystemic shunt;
this approach is indicated for patients with cirrhosis with
portal hypertension caused by portal vein thrombosis.6,7
The transhepatic is technically simpler than the transjugular
approach; the main disadvantage of the transhepatic route
is the risk of bleeding, especially in patients receiving anti-
coagulation therapy and in patients with ascites. Although
Fig 2. A, Contrast-enhanced CT scan shows distended SMV with large filling defect (arrow). B, Transhepatic
venogram, anteroposterior view, shows thrombosis of proximal SMV (arrow) extending into proximal portal vein
(arrowhead). C, Control venogram, anteroposterior view, after mechanical thrombectomy shows widely patent SMV
(arrow) and patent proximal portal vein (curved arrow). D, Control CT scan after thrombectomy shows patent SMV
(arrow).
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we did not observe any complications in our three patients,
significant intraabdominal bleeding is a potential serious
complication.5 The use of a small gauge Chiba needle
(Cook) with ultrasonic guidance to catheterize the portal
vein and embolization of the liver tract with coils or gel-
foam plugs at the conclusion of the procedure decreases
significantly the risk of bleeding. The procedure can be
safely performed with local anesthesia.9
Mechanical thrombectomy is a promising new tech-
nique for the treatment of acute MVT, especially in patients
at high risk for pharmacologic thrombolytic therapy.7 The
use of mechanical devices offers the potential to reduce
procedure times and reduce or eliminate the need for
pharmacologic agents. In two of our patients with focal
thrombosis of the veins, the use of thrombectomy devices
allowed us to clear the thrombus completely in a fast and
efficient way, without the additional time, risk, and cost of
a continuous infusion of thrombolytics. In patients with
extensive thrombosis of the portal and mesenteric system,
mechanical devices could initially be used to debulk the
thrombus. Pharmacologic thrombolysis would probably
still be necessary in most cases to treat residual thrombosis
and to treat thrombus in the small and peripheral veins. The
combination of mechanical and pharmacologic agents may
significantly decrease treatment times in patients with ex-
tensive thrombosis. We used two different types of throm-
bectomy devices. One device, the Oasis thrombectomy, is a
triple lumen catheter with a J-shaped fine stainless steel
channel that directs a high-pressure saline jet into the clot.
The unit is driven with a conventional angiographic injec-
tor. This device cleared the clot completely in one case with
focal thrombosis; in the second patient, the clot was prob-
ably adhered the wall of the SMV and the Oasis device
failed to dissolve the thrombus. The second device, the
Arrow-Trerotola thrombectomy, successfully cleared the
clot in the second patient with a short activation time. This
device consists of a nitinol fragmentation basket that is
attached to a rotator unit. The device rotates at 3,000 rpm,
resulting in pulverization of the clot in particles less than 3
mm.19 The Arrow-Trerotola device has been extensively
used to declot synthetic dialysis grafts; although preclinical
studies have only shown limited endothelial injury, we do
not recommend its use in native veins until further studies
assess its safety.20
In conclusion, we described the successful treatment of
symptomatic MVT in three patients with pharmacologic
and mechanical thrombolysis through a transhepatic access,
followed by embolization of the liver tract. The procedure
was effective in treating focal thrombosis in two patients
and extensive thrombosis in one patient. Endovascular
treatment of MVT should be offered only to symptomatic
patients with early diagnosis. Minimally symptomatic pa-
tients may best be treated with systemic anticoagulation
only. Prompt surgical intervention should be undertaken if
the patient’s condition deteriorates or clinical signs of
peritonitis develop.
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